Hugel Inc Total Assets
Hugel Inc total assets. Based on the latest financial reports, Hugel Inc (145020) holds total assets worth ₩1.19 Trillion KRW (≈ $807.81 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hugel Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Hugel Inc (2014–2025)
Total assets of Hugel Inc from 2014 to 2025. This chart illustrates how Hugel Inc's total assets have evolved over time, based on quarterly financial data. See Hugel Inc stock price for real-time trading data and today's change.
Hugel Inc - Asset Composition Analysis
Hugel Inc Total Assets Breakdown (December 2025)
Hugel Inc total assets breakdown as of December 2025. Hugel Inc's total assets of ₩1.19 Trillion consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 19.5% |
| Accounts Receivable | ₩74.99 Billion | 7.0% |
| Inventory | ₩55.85 Billion | 5.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩113.20 Billion | 10.5% |
| Goodwill | ₩78.11 Billion | 7.3% |
Asset Composition Trend (2014–2025)
This chart illustrates how Hugel Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hugel Inc (145020) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hugel Inc's current assets represent 63.1% of total assets in 2025, an increase from 53.7% in 2014.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, up from 17.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 10.5% of total assets.
Hugel Inc Competitors by Total Assets
Key competitors of Hugel Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Hugel Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.55 | 7.32 | 15.93 |
| Quick Ratio | 6.99 | 6.76 | 15.27 |
| Cash Ratio | 0.00 | 0.00 | 1.15 |
| Working Capital | ₩663.19 Billion | ₩518.04 Billion | ₩567.04 Billion |
Hugel Inc - Advanced Valuation Insights
This section examines the relationship between Hugel Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 14.6% |
| Total Assets | ₩1.08 Trillion |
| Market Capitalization | $1.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hugel Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hugel Inc's assets grew by 14.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hugel Inc (2014–2025)
The table below shows the annual total assets of Hugel Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.08 Trillion ≈ $729.76 Million |
+14.63% |
| 2024-12-31 | ₩939.44 Billion ≈ $636.64 Million |
+1.10% |
| 2023-12-31 | ₩929.25 Billion ≈ $629.74 Million |
-11.48% |
| 2022-12-31 | ₩1.05 Trillion ≈ $711.42 Million |
+3.97% |
| 2021-12-31 | ₩1.01 Trillion ≈ $684.28 Million |
+5.58% |
| 2020-12-31 | ₩956.34 Billion ≈ $648.10 Million |
+6.89% |
| 2019-12-31 | ₩894.69 Billion ≈ $606.32 Million |
-2.57% |
| 2018-12-31 | ₩918.27 Billion ≈ $622.30 Million |
+11.86% |
| 2017-12-31 | ₩820.93 Billion ≈ $556.33 Million |
+178.94% |
| 2016-12-31 | ₩294.30 Billion ≈ $199.44 Million |
+26.00% |
| 2015-12-31 | ₩233.57 Billion ≈ $158.29 Million |
+140.18% |
| 2014-12-31 | ₩97.25 Billion ≈ $65.90 Million |
-- |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more